Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of Gerilimzumab in Healthy Adults
NCT04178070Phase 1Unknown
- Sponsor
- Genor Biopharma
- Start
- Nov 2017
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gerilimzumab in rheumatoid arthritis (RA) (12 arms), sponsored by Genor Biopharma. Primary endpoints: Adverse Effect up to 112 days, Serious Adverse Effect up to 112 days and 2 more. Status: unknown.
02
Drugs
gerilimzumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04178070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04178070.